Oncolytic adenovirus Ad657 for systemic virotherapy against prostate cancer.
Tien V NguyenCatherine M CrosbyGregory J HellerZachary I MendelMary E BarryMichael A Barry
Published in: Oncolytic virotherapy (2018)
These data suggest that Ad657 may have utility as a local or systemic oncolytic virotherapy for prostate cancers. These data also lay the foundation for serotype-switching with oncolytic species C Ads.